Resources from the same session
Clinical development of KRAS G12C inhibitors – where are we now?
Presenter: Z. Li, CN
Session: Session 2 – Targeting KRAS G12C in Lung Cancer
Resources:
Slides
Webcast
Moving forward with KRAS G12C inhibitors – combinations (only chemotherapy and targeted therapy sequencing)
Presenter: F. Skoulidis, US
Session: Session 2 – Targeting KRAS G12C in Lung Cancer
Resources:
Slides
Webcast